Dudediligence.

Revolution Medicines, Inc

RVMDNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$0.00Dec ’24
Net income, by quarter
−$156.3MSep ’24−$194.6MDec ’24−$213.4MMar ’25−$247.8MJun ’25−$305.2MSep ’25−$364.6MDec ’25−$453.8MMar ’26−$644.4MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$29.4M$35.4M$11.6M$0.00$0.00
Operating income−$188.0M−$258.3M−$487.2M−$689.5M−$1.18B
Net income−$187.1M−$248.7M−$436.4M−$600.1M−$1.13B
Operating cash flow−$147.2M−$224.4M−$350.6M−$557.4M−$897.7M
Free cash flow−$153.7M−$235.2M−$358.3M−$567.7M−$913.7M
Cash$108.5M$161.4M$696.1M$543.1M$383.7M
Shares outstanding74.1M90.4M164.7M185.9M197.0M